Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment

Cancers (Basel). 2024 Dec 12;16(24):4145. doi: 10.3390/cancers16244145.

Abstract

Lung cancer is a deadly disease with the highest rates of mortality. Over recent decades, a better understanding of the biological mechanisms implicated in its pathogenesis has led to the development of targeted therapies and immunotherapy, resulting in improvements in patient outcomes. To better understand lung cancer tumor biology and advance towards precision oncology, a comprehensive tumor profile is necessary. In recent years, novel in situ spatial multiomics approaches have emerged offering a more detailed view of the spatial location of tumor and tumor microenvironment cells, identifying their unique composition and functional status. In this sense, novel multiomics platforms have been developed to evaluate tumor heterogeneity, gene expression, metabolic reprogramming, signaling pathway activation, cell-cell interactions, and immune cell programs. In lung cancer research, several studies have used these spatial technologies to locate cells and associated them with histological features that are relevant to the pathogenesis of lung adenocarcinoma. These advancements may unveil further molecular and immune mechanisms in tumor biology that will lead to the discovery of biomarkers for treatment prediction and prognosis. In this review, we provide an overview of more widely used and emerging pathology-based approaches for spatial immune profiling in lung cancer and how they enhance our understanding of tumor biology and immune response.

Keywords: immune profiling; lung carcinoma; spatial cellular analysis.

Publication types

  • Review

Grants and funding

This study was supported by Lung Cancer SPORE P50 CA070907 and the Translational Molecular Pathology-Immuno-profiling laboratory Moonshot Platform (TMP-IL) at the Department of Translational Molecular Pathology at the University of Texas MD Anderson Cancer. Scientific and financial support for the Cancer Immune Monitoring and Analysis Centers-Cancer Immunologic Data Commons (CIMAC-CIDC) Network is provided through the National Cancer Institute (NCI) Cooperative Agreement, U24CA224285 to the MD Anderson Cancer Center CIMAC. The authors also thank the FHU OncoAge (University Côte d’Azur) for supporting the fee charges concerning the manuscript.